PGPratiti Ghosh

Pratiti Ghosh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pratiti Ghosh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In Silico Screening and Validation of Natural Components as Novel P-glycoprotein Inhibitors to Enhance the Bioavailability of Cancer Drugs

    by Swagata Mukhopadhyay, Sayak Ganguli, Pratiti Ghosh

    Background: Multidrug resistance in cancer arises when p-glycoprotein is overexpressed, actively expelling chemotherapeutic agents from cancer cells, thereby lowering their intracellular concentrations and diminishing the effectiveness of conventional therapies. However, in silico and docking-based screening of natural compounds offers a promising approach to identify selective, low-toxicity p-glycoprotein inhibitors that could help restore the efficacy of these drugs. Aim: The objective of this study was to use an in silico approach to study the potential of spice constituents as p-glycoprotein inhibitors, with the possibility that they may increase the bioavailability of co-administered cancer medications by decreasing their efflux from cancer cells. Methods: Virtual screening was employed to screen 16 bioactive components from 9 spices for their potential to interact with p-glycoprotein. The binding affinity and binding stability of these interactions were predicted using molecular docking and molecular dynamics simulations in the Biovia Discovery Studio software. Results: 7 components were identified with high binding affinities for p-glycoprotein, suggesting their potential as inhibitors. The compounds with the highest binding affinities for p-glycoprotein were hydroxymatairesinol, gingerenone-A, curcumin, and pinoresinol. Conclusion: The results of this study have proposed that hydroxymatairesinol from Sesamum indicum and gingerenone-A from Zingiber officinale, may be considered potential inhibitors of p-glycoprotein. Major Findings: The in silico analysis identified seven spice-derived compounds with strong predicted binding affinities toward p-glycoprotein, with Hydroxymatairesinol (from sesame) and GingerenoneA (from ginger) among the top binders, suggesting they may serve as promising, low-toxicity p-glycoprotein inhibitors to enhance chemotherapeutic drug retention in cancer cells.

  • Open Access

    Fruit Bioactive Compounds as P-Glycoprotein Inhibitors - An In-Silico Study

    by Ayantika Kundu, Biswadev Bishayi, Pratiti Ghosh

    Introduction: P-glycoprotein is a crucial efflux transporter whose overexpression contributes to drug resistance, hindering effective treatment of various diseases. Objective: This study aims to identify the inhibitory bioactive fruit components on p-glycoprotein, which could potentially overcome drug resistance. Methodology: 150 bioactive components were identified from 40 regional fruits from India. The druggability and pharmacokinetic profiles of the components were examined, revealing 8 potential inhibitors. Molecular docking was performed to identify the most suitable inhibitor, which was then subjected to simulation to validate its interaction with p-glycoprotein. Result: According to our research, Δ5-Avenasterol (−79.5 kcal/mol) and Phyllanthin (−78.8 kcal/mol) have a comparable binding affinity to the control inhibitor rifampin (−73.6 kcal/mol), making them appropriate inhibitors for p-glycoprotein. Conclusion: The conformational stability of the most effective inhibitory drugs inside the p-glycoprotein structure was evaluated using molecular dynamics simulations. This research may lead to the development of novel natural p-glycoprotein inhibitors, providing a promising strategy for combating multidrug resistance.

  • Open Access

    Rauwolfia serpentina in P-Glycoprotein Inhibition of Cancer & Diabetes - A Computational Study

    by Chandana Roy, Sayak Ganguli, Pratiti Ghosh

    Background: The efficient treatment of cancer and diabetes is often constrained by reduced permeation of chemotherapeutic and antidiabetic medications due to p-glycoprotein-mediated efflux, impeding their therapeutic potential and necessitating higher doses or prolonged treatments, which can lead to increased toxicity and financial burden. Ayurveda, an ancient holistic healthcare system, advocates the use of herbal remedies for various ailments. Objective: This study aims to explore the potential of Rauwolfia serpentina and other selected antidiabetic and anticancer medicinal herbs as inhibitor of p-glycoprotein. Materials and Methods: Druggability and pharmacokinetic profile of 185 herbal constituents were evaluated and their binding affinity were interpreted against 6C0V structure of p-glycoprotein utilizing molecular docking with CDOCKER program of Discovery Studio. The stability of the docked complex was validated using molecular dynamics simulation for 40 nanoseconds. ChemMine software was employed for clustering p-glycoprotein herbal inhibitors against standard drug verapamil on the basis of physicochemical properties. Results: Docking analyses revealed that deserpidine and ajmalicine from Rauwolfia serpentina exhibited strong favourable binding interactions with p-glycoprotein, along with other herbal compounds viz., hydrastine from Hydrastis canadensis, palmatine from Tinospora cordifolia and hexadecanoic acid 2-hydroxy-1(hydroxymethyl)ethyl ester from Ipomoea aquatica. Conclusion: This study underscores the potential of combining Rauwolfia serpentina and other medicinal herbs with allopathic drugs to augment their bioavailability and efficacy, providing a novel avenue for advancing therapeutic strategies in oncology and diabetes management. Further experimental validation is necessary to confirm the clinical relevance of these findings.


  • Open Access

    Exploring the Potential of Phytoconstituents for Immunomodulation as Natural Inhibitors of P-glycoprotein - A Computational Study

    by Chandana Roy, Sayak Ganguli, Pratiti Ghosh

    Background: P-glycoprotein is an efflux transporter found on the walls of internal organs that interact with the environment, to reduce bioavailability of xenobiotics and chemotherapeutic drugs. Co-administration of herbal medicinal components as modulators or inhibitors may configure the transporter in favour of the drug, thus restricting its expulsion. Aim: The present study aims to explore such herbal medicinal components as potential p-glycoprotein inhibitors thus analyzing the possibility for retaining co-administered immunomodulatory medicines within target cells. Methods: Druggability and pharmacokinetic attributes of the natural compounds were analyzed. Molecular docking using CDOCKER program of Discovery studio (version 2019-21) was utilized to analyze the binding affinity between the natural compounds and 6C0V receptor. Molecular dynamics simulation was employed to evaluate the stability of potential binding compounds. Results: Molecular docking analyses of 462 components from 30 herbs revealed that the inhibitors viz., chelidonine, dihydroberberine, stylopine, fumariline from Chelidonium majus; akuammigine, echitamine from Alstonia scholaris; arjunone from Terminalia arjuna and pareirubrine A from Cissampelos pareira displayed strong binding affinity towards p-glycoprotein. Conclusion: These lead compounds viz., chelidonine, akuammigine and echitamine bearing the maximum binding potency, are known components of immune enhancing herbs. We propose that these molecules may be used in conjunction with immunomodulatory drugs to enhance their bioavailability.

  • Open Access

    Spice components as modulating agents of P-glycoprotein – An in silico study

    by Swagata Mukhopadhyay, Chandana Roy, Pratiti Ghosh

    P-glycoprotein acts as a protective barrier against xenobiotics and cellular toxicants in the human body while playing an important role in drug transportation in many organs. Overexpression of p-glycoprotein can lead to a decrease in the absorption of many drugs. After screening, 33 phytochemicals from 25 spices were selected for docking with p-glycoprotein to detect some naturally occurring p-glycoprotein inhibitors to modulate multidrug resistance. Absorption, distribution, metabolism, excretion, and toxicity prediction and drug-like properties of those ligands were investigated from pkCSM, Molinspiration, and SwissADME software, followed by molecular docking study and molecular dynamic simulation on BIOVIA Discovery Studio. These 33 phytochemicals met the criteria of p-glycoprotein inhibitor as much as the reference drug verapamil. Pandamarilactone-31 showed the highest binding affinity for p-glycoprotein, acting as the lead p-glycoprotein inhibitor, followed by α-D-fructofuranoside methyl, sesamolinol, and nigellidine.


  • Open Access

    Expression of Oestrogen Receptor Alpha (ERα) in Oral Lichen Planus – A Precancerous Inflammatory Disease in Middle-Aged Females

    by Abhishek Jana, Jincy Thomas, Pratiti Ghosh

    Background: Oral lichen planus (OLP) is an autoimmune disease primarily affecting the middle-aged females. The present study aims to determine the relation of the oestrogen receptor alpha (ERα) with OLP pathogenesis, correlating it with the possible cause of its higher prevalence among females. Materials and Methods: Clinically and histologically identified fifteen of each pre-menopausal and peri-menopausal OLP female patients were chosen for this study. The expression of ERα was analysed from the collected lesion tissue samples by using two-step semi-quantitative reverse transcriptase polymerase chain reaction (SqRT-PCR) and enzyme-linked immunosorbent assay (ELISA). Results: mRNA and protein expression of ERα were significantly higher in both groups of OLP female patients when compared with the control. The perimenopausal OLP patients showed significantly elevated expression of ERα compared to premenopausal patients. Conclusion: Higher expression of ERα in pre- and peri-menopausal females may be a causative factor for the higher prevalence of OLP among females.


  • Open Access

    Co-administration of herbal inhibitors of P-glycoprotein with renal drugs enhance their bioavailability– In silico approach

    by Chandana Roy, Pratiti Ghosh

    Introduction: Multidrug resistance (MDR) is primarily associated with reduced intracellular drug accumulation owing to overexpression of p-glycoprotein, an active efflux transporter. Competitive inhibition or allosteric modulation of p-glycoprotein may alter the pharmacokinetics of the drugs that serve as substrates, resulting in enhanced drug bioavailability and tissue penetration. This study endeavors to assess the efficacy of the components of reno-protective herbs in the inhibition of p-glycoprotein activity thereby enhancing the possibility of the retention of co-administered renal medications inside the target cells. Methods: Drug-likeness and pharmacokinetic properties were determined to ensure the safety and efficacy of herbal constituents. Molecular docking employing the CDOCKER module of Discovery Studio was performed to investigate the binding affinity between the active constituents and the p-glycoprotein receptor (6C0V). Molecular dynamics simulation was utilized to further assess the stability of the complex of receptors with the component bearing its maximal affinity. Results: The analyses suggested that the inhibitors viz., atisine, kutkin, and embelin from Aconitum heterophyllum, phylloquinone from Calendula officinalis, stigmasterol from Paederia foetida, and convallamarogenin from Convallaria majalis demonstrated maximum binding affinity towards p-glycoprotein. Conclusion: Atisine may thus be identified as the lead compound in the augmentation of drug bioavailability inside the cell, along with its reno-protective efficacy.